Kanneboyina Nagaraju is the Dean of the School of Pharmacy and Pharmaceutical
Sciences at Binghamton University and a SUNY Distinguished Professor of
Pharmaceutical Sciences. He joined as the founding chair of the Department of
Pharmaceutical Sciences and was one of the initial leadership members to start a new
pharmacy school in 2016. His over 28 years of academic and research tenure spans the
prestigious National Institutes of Health, Johns Hopkins University School of Medicine in
Baltimore, George Washington University School of Medicine and Health Sciences, and
Children’s National Hospital in Washington, DC. He and his colleagues are credited with
discovering and developing AGAMREE (Vamorolone), a first-in-class dissociated
glucocorticoid with a significantly reduced side effect profile. The Food and Drug
Administration and European Medicines Agency have recently approved AGAMREE.
He is an academic entrepreneur who co-founded two successful biotechnology
companies, ReveraGen BioPharma Inc and Agada Biosciences and is engaged in
discovering and developing therapies for neuromuscular diseases. Dr. Nagaraju is an
internationally recognized leader in neuromuscular diseases (NMD). He has led
international efforts to improve rigor and reproducibility by developing reliable and
sensitive outcome measures to test drug efficacy in NMD models in collaboration with
TREAT-NMD. He is described as an exceptional mentor and empathetic leader with
outstanding interpersonal skills.
Cure Rare Disease, a non-profit organization (Tax ID number 82-2473513), is qualified as a tax-exempt organization under section 501(c)(3) of the IRS and has been designated as a “public charity” under section 170.
© CURE RARE DISEASE. ALL RIGHTS RESERVED.
.png)
© CURE RARE DISEASE.ALL RIGHTS RESERVED.
